

Annual Meeting - Vice Chairman and Chief Executive Officer Presentation

MINNEAPOLIS, United States and BRISBANE, Australia 4 December 2025: Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, is pleased to provide the attached Vice Chairman and Chief Executive Officer Presentation to the Annual Meeting.

ENDS

About Anteris

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris' lead product, the DurAVR[®] Transcatheter Heart Valve (THV), was designed in collaboration with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR[®] THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR[®] THV is made using a single piece of molded ADAPT[®] tissue, Anteris' patented anti-calcification tissue technology. ADAPT[®] tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR[®] THV System is comprised of the DurAVR[®] valve, the ADAPT[®] tissue, and the balloon-expandable ComASUR[®] Delivery System.

Authorisation and Additional information

This announcement was authorised for release on the ASX by the Vice Chairman and Chief Executive Officer.

For more information:

Investor Relations

investors@anteristech.com
Debbie Ormsby
Anteris Technologies Global Corp.
+61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)

mchatterjee@bplifescience.com
Malini Chatterjee, Ph.D.
Blueprint Life Science Group
+1 917 330 4269

Website www.anteristech.com
X @AnterisTech
LinkedIn <https://www.linkedin.com/company/anteristech>



ersonal use only

ANTERIS[®]

TECHNOLOGIES

Annual Meeting December 2025

NASDAQ: **AVR** | ASX: **AVR**



Disclaimer



Forward-Looking Statements

This presentation (including oral commentary that accompanies this presentation) contains forward-looking statements, including statements related to our business, products and clinical trials and studies. Any statements about our expectations, beliefs, plans, predictions, forecasts, objectives, assumptions, or future events or performance are not historical facts and may be forward-looking. In some cases, you can identify forward-looking statements through the use of words such as “believes,” “expects,” “may,” “will,” “should,” “would,” “seeks,” “intends,” “plans,” “pro forma,” “estimates,” “contemplates,” “aims,” “continues,” “anticipates” and similar expressions. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements are not guarantees of future performance and involve risks and uncertainties which are subject to change based on various important factors, some of which are beyond our control. Among the factors that could cause actual results to differ materially from those suggested by forward-looking statements are: our current and future research and development activities, including clinical testing and manufacturing and related costs and timing; sufficiency of our capital resources; our product development and business strategy, including the potential size of the markets for our products and future development and/or expansion of our products in our markets; our ability to commercialize products and generate product revenues; our ability to raise additional funding when needed; any statements concerning anticipated regulatory activities, including our ability to obtain regulatory clearances; our research and development expenses; and risks facing our operations and intellectual property; and the other risks described in our Annual Report on Form 10-K for the year ended December 31, 2024 and the other filings we make with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize or should any of these assumptions prove to be incorrect, our actual future results, performance and events and circumstances may differ in material respects from the performance projected in these forward-looking statements. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake any obligation to update any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in the Company’s expectations, except as may be required by law. Accordingly, the Company cautions you not to place any undue reliance on any forward-looking statements.

Industry Data

This presentation also includes data, forecasts and information obtained from industry publications and other information available to us. Some data is also based on our good faith estimates, which are derived from management’s knowledge of the industry and independent sources. We have not independently verified any of the data from third-party sources, nor have we ascertained the underlying assumptions relied upon therein. While we are not aware of any misstatements regarding the industry data presented herein, estimates and forecasts involve uncertainties and risks and are subject to change based on various factors.

Disclaimer



Non-GAAP Financial Measures

This presentation includes a discussion of our operating spend, which is an unaudited financial measure that is not based on any standardized methodology prescribed by U.S. generally accepted accounting principles (GAAP) and may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Operating spend should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. We use this non-GAAP financial measure as a measure of our operating performance. Management believes this measure allow management to more effectively evaluate our operating expenses and compare the results of our operations from period to period. We believe that this measure is useful to our investors because it provides a more complete understanding of the factors and trends affecting our business than could be obtained without such measure.

No Offer or Solicitation


This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Sales and offers to sell our securities will only be made in accordance with the Securities Act of 1933, as amended, and applicable SEC regulations, including written prospectus requirements. You should read the documents we file with the SEC for more complete information about us. You can obtain these documents for free by visiting EDGAR on the SEC's website at www.sec.gov.

ersonal use only

ersonal use only

ersonal use only

Leading the Field



BAHRAIN
GRAND PRIX
2022





Fig.10

1,800

1,600

1,400

1,200

1,000

800

600

400

200

0



Fig.11

Fig.12



Fig.14

6,987

8,795

FY2024 Key Numbers

CASH
\$70.5M*

Compared to \$21.1M
at Dec 31, 2023

136.1*

EMPLOYEES &
CONTRACTORS
FTE supporting Anteris'
business strategy
↑ 41.2%

CAPITAL RAISED
IN 2024
\$125.9M

Including IPO

R&D COSTS
\$51.5M

Compared to
\$30.9M in 2023
↑ 66.6%

All amounts are in USD
Percentages reflect year-on-year change
* As of December 31, 2024

Personal use only

Key 2025 Highlights

CASH
\$9.1M*

Compared to \$70.5M
at Dec 31, 2024

159.9*

EMPLOYEES &
CONTRACTORS

FTE supporting Anteris'
business strategy

↑ 41.2% since
Dec 2024

Q4 2025
PRIVATE PLACEMENT

\$25.2M

GROSS PROCEEDS

R&D COSTS*

YTD 9 MONTHS

\$49.6M

COMPARED TO \$38.1M
FOR 9 MTHS IN 2024

↑ 30.1%

Q4 2025

**REGULATORY
APPROVALS**

received to start the
PARADIGM pivotal study in
Denmark and the U.S.

All amounts are in USD

* As of September 30, 2025




Focused R&D Expenditures Driving the Path to Approval

Research and Development Costs

- PARADIGM trial preparatory costs
- Expansion of clinical field team
- Upscaling manufacturing capabilities
- DurAVR[®] valve development program
- EMBARK clinical trials / US EFS
- v2v research
- Expansion of medical affairs team

Driving Innovation: R&D is 76.4% of our operating spend¹



¹Operating spend reflects US GAAP operating costs adjusted to exclude stock-based payments. Operating spend is a non-GAAP financial measure. Please refer to the reconciliation on the next slide.



Reconciliation of R&D expenditures to Operating spend

		12 months Dec 31, 2023 \$M ¹	12 months Dec 31, 2024 \$M ¹	9 months Sept 30, 2025 \$M ²
Research & Development expense (R&D)				
Total R&D disclosed in Forms 10-K and 10-Q		30.9	51.5	49.6
Stock-based compensation expense related to R&D (non-cash)		(2.7)	(0.8)	(2.4)
R&D excluding stock-based compensation expense	(a)	28.2	50.7	47.2
Operating spend				
Cost of products sold		1.9	1.4	0.5
Research and development expense		30.9	51.5	49.6
Selling, general and administrative expense		17.4	28.2	16.4
Acquired in-process research and development		0.1	-	-
Total operating expenses disclosed in Forms 10-K and 10-Q		50.2	81.1	66.5
Stock-based compensation expense relating to operating expenses		(6.5)	(6.0)	(4.7)
Total operating expenses excluding stock-based compensation expense	(b)	43.7	75.1	61.8
R&D as a percentage of our Operating spend	(a)/(b)	64.5%	67.5%	76.4%

Some amounts may not reconcile due to rounding.

¹ Source: Annual report on Form 10-K for the year ended December 31, 2024:

- ◆ Consolidated Statements of Operations
- ◆ Stock-based compensation – Note 16(a)

² Source: Quarterly report on Form 10-Q for the period ended September 30, 2025:

- ◆ Consolidated Statements of Operations
- ◆ Stock-based compensation – Note 8(a)




Positive FX Impact Linked to Decline in AUD





Positive FX Impact Linked to Decline in AUD



- AUD 10.4M of expenses incurred in YTD Sept 2025 converted into USD 6.7M
- The same AUD 10.4M using the prior 10-year average FX rate converts into USD 7.4M

ersonal use only

Access to
Capital Has
Increased With
Our Data !




**Institutional
investor**



Continued Institutional Support

- Top shareholders continue to demonstrate **strong support**
- Concentrated ownership among **high-quality, physician-led** institutional investors
- Since IPO, mix of top 20 **shareholders shifted to the US**
- Greater than **10-fold increase** in liquidity (volume) since US IPO
- On-going engagement with **leading investors**

SHAREHOLDER MIX



ersonal use only




Ongoing Large Shareholder and New Institutional Support

ersonal use only

- On-going support reflects **confidence in the Company's strategy** and clinical progress
- Strong engagement with **leading investors**
- **95%+ of funds** raised in recent capital placements from existing large institutional holders and new institutional investors


Capital placements - funds raised






Building a Strong, Global Workforce

Workforce by Function



Workforce by Geography



Employees & Contractors 159.9 FTE
Gender diversity Male 41%, Female 59%


* Data as of September 30, 2025, includes contractors

Personal use only




Building a Strong, Diverse & Inclusive Workforce

FTE BY FUNCTION



GENDER DIVERSITY



September 30, 2025

Leadership and Management: 51% Male / 49% Female

Employees & Contractors: 159.9 FTE

↑ 17.5% (23.8 FTE) from December 2024

95.3% of growth attributable to R&D

* Data as of September 30, 2025, including employees & contractors

Personal use only



Building a Strong, Diverse & Inclusive Workforce

ersonal use only

Celebrating our Ethnic Diversity



Inclusive and Collaborative

Driving Innovation Through Diversity

Our People, Our Strength

Representation Matters

NASDAQ

Setting Up a Structure For the Future


ersonal use only





2024 Re-Domiciliation and US IPO

- **Re-domiciled from Australia to US** end of 2024 (Anteris Technologies Global Corp new parent)
- **Strong support** from shareholders and option holders
- **Listed common stock on the Nasdaq** and CDIs on the ASX
- **IPO raising USD 88.8M , AUD 135M** (gross proceeds)




ersonal use only



Liquidity Has Increased Over 1000% Since Nasdaq


Monthly liquidity



ersonal use only



AVR Stock Price Movements





How Do We Compare to Newly Listed Small Cap MedTechs ?

First MedTechs listed in approx 3 years


16.97 USD

-11.82 (-41.06%) ↓ past year

Closed: Nov 28, 5:00 PM EST • [Disclaimer](#)

After hours 16.97 0.00 (0.00%)

1D | 5D | 1M | 6M | YTD | 1Y | 5Y | Max




Market Summary > Anteris Technologies Global Corp

4.10 USD

-1.50 (-26.79%) ↓ past year

Nov 28, 1:05 PM EST • [Disclaimer](#)

1D | 5D | 1M | 6M | YTD | 1Y | 5Y | Max





Stock Volatility Follows the Market


Market Summary > Anteris Technologies Global Corp

4.10 USD

+0.73 (21.66%) ↑ past 5 days

28 Nov, 1:05 pm GMT-5 • [Disclaimer](#)

1D | **5D** | 1M | 6M | YTD | 1Y | 5Y | Max



ersonal use only



ersonal use only

A Chat with Dr Chris



Being Normal As a Company In This Space Was Never The Target



But Bringing
Patients Back
To a Normal
State Was



ersonal use only


Unpacking the Clinical Data






DurAVR[®] THV: A New Class of TAVR

Single piece, native-shaped biomimetic design built to mimic the performance of a healthy aortic valve



**Anti-Calcification,
Anti-Fibrotic ADAPT[®] Tissue**



**Long Coaptation
To Reduce Stress**




**Balloon Expandable
Precision**



**Commissure Alignment
Technology**



**Coronary
Access**




ersonal use only




DurAVR[®] Only THV to Demonstrate Restoration of Physiologic Laminar Flow



Healthy Aortic Valve




Post DurAVR[®] THV



Post DurAVR[®] THV



FD = 10% FRR = 1%



FD = 14% FRR = 4%


FD = Flow Displacement, FRR = Flow Reversal Ratio
Courtesy of Dr. Pankaj Garg, Norwich University Hospital (UK)
Data presented at New York Valves 2024

Personal use only

the PCR App
at your fingertips

QUESTIONS
in the live chat

RATE
the session



Search for PCR in the App Store
or Google Play.




SPEAKERS
names and roles

INTERVENTIONS
schedule


Sponsored by Meril

Hemodynamics and PPM in Small Annuli at 30 Days



Single-digit mean gradient



Large EOA



Low rate of moderate or severe
prosthesis-patient mismatch



1. Entel et al. JACC 2019; 73:1000-1010
2. Pibarot et al. ESCV 2019; 16:1-10
PCR London Valves is a registered trademark of PCR. All other trademarks are the property of their respective owners.

Keep the PCR App
at your fingertips

QUESTIONS
in the live chat

RATE
the session



SPEAKERS
names and roles

INTERVENTIONS
schedule

Personal use only



ersonal use only

Just Published!

EuroIntervention

Official Journal of EuroPCR and the European Association
of Percutaneous Cardiovascular Interventions (EAPCI)

Thirty-day outcomes
of a novel biomimetic
balloon-expandable
transcatheter heart
valve in patients with
small aortic annuli

DurAVR[®]
TRANSCATHETER HEART VALVE



DurAVR[®] THV Small Aortic Annuli Pooled Cohort

Symptomatic Severe Native Aortic Stenosis

EMBARK
Study

DurAVR S Valve
N=74

30-Day Follow-up
N=74

US EFS

DurAVR S Valve
N=15

30-Day Follow-up
N=15

EU EFS

DurAVR S Valve
N=11

30-Day Follow-up
N=11

DurAVR[®] THV Small Aortic Annuli (SAA) Pooled Cohort
N=100

DurAVR[®] THV
Small Valve




Area: 346-452 mm²

ersonal use only


Procedural Success Across Variety of Anatomies

Challenging anatomies treated


Severe annular calcium




Extreme leaflet calcium




Type 1 bicuspid



Extreme LVOT calcium



Technical success: 93%
Device success: 91%




Baseline Echo and CT Characteristics


Baseline Echo and CT Characteristics	DurAVR [®] THV (N=100)
Aortic annulus area, mm ²	404 ± 37
Aortic annulus mean diameter, mm	22.7 ± 1.0
Aortic valve area, cm ²	0.8 ± 0.2
Mean transvalvular gradient, mmHg	48.1 ± 17.0
Left ventricular ejection fraction, %	58.0 ± 7.0

Favorable Hemodynamics Through 30 Days


Single-digit mean gradient and large effective orifice area



No moderate or severe paravalvular leak




97% freedom from ≥ moderate prosthesis-patient mismatch




Hemodynamics and PPM in Small Annuli at 30 Days


Single-digit mean gradient



Large EOA



Low rate of moderate or severe prosthesis-patient mismatch



Error bars represent standard deviation

1. Hermann HC et al. NEMJ. 2024;390:1957-71.

2. Presented by Hermann HC SCAI 2024: SEV vs. BEV TAVR in patients with small aortic annuli: Additional outcomes from the SMART Trial.

CHANGING THE TREATMENT PARADIGM



PARADIGM Trial Design

Severe Native Aortic Stenosis

All Comers Randomized Cohort

Assessment for Eligibility
All Risk Candidate

1:1 Randomization
N=1054

DurAVR®

Commercially Available TAVR

Low Risk Randomized Cohort

Assessment for Eligibility
Low Risk Candidate

1:1 Randomization
N=446

DurAVR®

Commercially Available TAVR

10-Year Follow-up

Primary Endpoint: Composite of all-cause mortality, all stroke, and CV hospitalization at one year

Primary Endpoint: Composite of all-cause mortality, all stroke, and CV hospitalization at two years

Failed Surgical Bioprosthesis Cohort

Valve-in-Valve Cohort

Assessment for Eligibility
High-Risk Candidate

DurAVR®
N=150

5-Year Follow-up


Primary Endpoint: Composite of all-cause mortality, all stroke, and CV hospitalization at one year

CT and MRI Sub-Studies

ersonal use only

Experience Matters

Clinical, Manufacturing, Launch





A Very Experienced Clinical Trial Team

Total culminative amount of clinical studies that current Anteris employees have been instrumental in successfully delivering:

163

Spanning cardiovascular devices, regulatory affairs, and medical leadership across global markets

68

US Clinical and Regulatory Affairs

55

EU Clinical and Regulatory Affairs

19

US & EU Medical Affairs


21

Executive Management Board

Personal use only

ersonal use only

What Else Do We Need?



We Have a World Class Experienced Team Across All Areas

- VP of RA has filed for multiple approvals from one of the big MedTechs
- VP Manufacturing was Head of Global TAVR manufacturing at one of the big MedTechs
- VP QC was head of QC at of the Big MedTechs
- Clinical Field team all come from TAVR backgrounds from the big MedTechs
- Head of Medical Affairs is from a TAVR background from one of the big MedTechs
- Head of Marketing is from one of the big MedTechs
- The team has dozens of global product launches between them worth billions of dollars



ersonal use only


ersonal use only

WHAT'S NEXT





Pivot From Rx Co to MedTech - A High Risk But Necessary Strategy



What's Next?

1

Additional Regulatory Approvals to commence PARADIGM

2

Patient Follow up (1mth, 1 yr)

3

Completion of Enrolment

4

PMA and CE Mark Submissions

5


Commercialization



TAVR Market Opportunity Expected to Reach USD 9.9BN in 2028

Underpenetrated patient population with only 15-20%¹ of severe aortic stenosis cases treated today

TAVR Aortic Stenosis & Valve-in-Valve Market²



Potential for further significant growth

Currently 3 industry trials in progress, anticipated to be completed in 2025



Edwards Lifesciences: SAPIEN 3 platform FDA approved for asymptomatic severe AS patients based on EARLY TAVR Trial (May 2025)



Edwards Lifesciences: will examine the TAVR procedure in patients who are > 65 years, have moderate AS, and have at least one additional risk factor



Medtronic: to explore the treatment of moderate AS with early TAVI implantation (TAVI) before AS becomes severe

1. Gahl B, Çelik M, Head SJ, et al. Natural History of Asymptomatic Severe Aortic Stenosis and the Association of Early Intervention With Outcomes: A Systematic Review and Meta-analysis. JAMA Cardiol. 2020;5(10):1102–1112. doi:10.1001/jamacardio.2020.2497.
2. Future Market Insights. Transcatheter Heart Valve Replacement (TAVR) Market: Global Industry Analysis 2016 – 2023 and Opportunity Assessment 2024 – 2034. Future Market Insights; 2024. Available from: <https://www.futuremarketinsights.com/reports/transcatheter-heart-valve-replacement-tavi-market>.



Value Proposition

Anteris has a compelling clinical proposition

Current Market Leader

Edwards Lifesciences

Shares outstanding as of Sept 30, 2025	580.7 million
Share price ^(a)	USD 86.67 AUD 132.32
Market capitalization	USD 50 billion AUD 77 billion
TAVR market share ^(b)	63.9%

New Entrant

Anteris Technologies

Shares outstanding as of Nov 12, 2025	41.2 million
Share price ^(c)	USD 4.10 AUD 6.26
Market capitalization	USD 169 million AUD 258 million
Potential TAVR market share	??
Potential market capitalization	??


(a) USD Closing price November 28, 2025. 1 AUD = 0.655 USD

(b) Worldwide TAVR \$ Market Share, Source: UBS Estimates; Company Reports, Visible Alpha March 2024

(c) Nasdaq USD Closing price November 28, 2025. 1 AUD = 0.655 USD

ersonal use only


Anteris is Leading the Field



DurAVR® THV
is the 1st to
quantifiably
demonstrate
restoration
of physiologic
laminar flow

DurAVR® THV is a registered trademark of Anteris, Inc. All other trademarks are the property of their respective owners. © 2018 Anteris, Inc. All rights reserved. Anteris, Inc. is an Equal Opportunity Employer. Anteris, Inc. is an Equal Opportunity Employer.

QUESTIONS







Board of Directors



John Seaberg
CHAIRMAN



Wayne Paterson
VICE CHAIRMAN & CEO



Stephen Denaro
DIRECTOR



Dave Roberts
NON-EXECUTIVE DIRECTOR



Greg Moss
NON-EXECUTIVE DIRECTOR



David St Denis
PRESIDENT & DIRECTOR

ersonal use only



Highly Experienced Leadership – Clinical, Operational, Commercial



Wayne Paterson

VICE CHAIRMAN & CEO



David St Denis

PRESIDENT & DIRECTOR



Matthew McDonnell

CHIEF FINANCIAL OFFICER



Dr. Chris Meduri

CHIEF MEDICAL OFFICER

ersonal use only

ersonal use only

Our Physician Advisors



ersonal use only

Our Visionary Investors



ersonal use only


And of Course Our Patients

A close-up photograph of a healthcare professional wearing blue nitrile gloves holding a patient's hand. The patient's face is partially visible in the background, looking down. Another hand is resting on the patient's arm, which has a white bandage and a small red mark. The scene is set in a clinical environment with a white background.

ersonal use only

Anteris is Leading the Field

DurAVR[®] THV
is the 1st to
quantifiably
demonstrate
restoration
of physiologic
laminar flow



DurAVR[®] THV is a transcatheter heart valve. DurAVR[®] THV is not available for commercial sale in the United States. DurAVR[®] THV is a registered trademark of Anteris, Inc. © 2018 Anteris, Inc. All rights reserved. DurAVR[®] THV is a registered trademark of Anteris, Inc. All rights reserved.

ersonal use only

THE



TEAM